Soon, more effective vaccines to help in fight against cancer

Image
ANI Washington
Last Updated : Mar 03 2014 | 12:30 PM IST

Researchers have described the earliest stages of fate determination among white blood cells called T lymphocytes, providing new insights that may help drug developers create more effective, longer-lasting vaccines against microbial pathogens or cancer.

Naive T lymphocytes patrol the front lines of the human body's defense against infection, circulating in blood and tissues, searching for invasive microbes and other foreign antigens.

They're called "naive" because they have not yet encountered an invader. When they do, these T cells activate and divide, giving rise to two types of daughter cells: "effector lymphocytes" responsible for immediate host defense and "memory lymphocytes" that provide long-term protection from similar infections.

John T. Chang, MD, assistant professor in the Department of Medicine and the study's co-principal investigator, along with Gene W. Yeo, PhD, assistant professor in the Department of Cellular and Molecular Medicine and Institute for Genomic Medicine, said that researchers have been trying for a very long time to understand when and how T lymphocytes give rise to effector and memory cells during an infection.

First authors Janilyn Arsenio, a postdoctoral fellow in the Chang lab and Boyko Kakaradov, a graduate student in the Yeo lab and UCSD Bioinformatics graduate program said that they took advantage of recent technological advances in single-cell gene expression profiling and cutting-edge machine-learning algorithms to address this question on a level of detail that was not previously possible.

Chang, Yeo and colleagues discovered that the decision by an individual T cell to produce effector and memory cells is made almost at the moment of infection. "The 'mother' lymphocyte seems to divide into two daughter cells that are already different from birth," said Chang, "with one becoming an effector cell while its sister becomes a memory cell."

The findings have been published online in the journal Nature Immunology.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 03 2014 | 12:14 PM IST

Next Story